Literature DB >> 21252140

Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen.

Margaret Lartey1, Kwamena W Sagoe, Hongmei Yang, Ernest Kenu, Fafa Xexemeku, Joseph Oliver-Commey, Vincent Boima, Markafui Seshie, Augustine Sagoe, Julius A A Mingle, Timothy P Flanigan, Hulin Wu, Awewura Kwara.   

Abstract

Viral decay rates during efavirenz-based therapy were compared between human immunodeficiency virus (HIV)-infected patients without tuberculosis (n = 40) and those with tuberculosis coinfection who were receiving concurrent antituberculous therapy (n = 34). Phase I and II viral decay rates were similar in the 2 groups (P > .05). Overall, concurrent antituberculous therapy did not reduce the efficacy of the HIV treatment.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21252140      PMCID： PMC3060905          DOI： 10.1093/cid/ciq196

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  25 in total

1.  Population HIV-1 dynamics in vivo: applicable models and inferential tools for virological data from AIDS clinical trials.

Authors:  H Wu; A A Ding
Journal:  Biometrics       Date:  1999-06       Impact factor: 2.571

2.  Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy.

Authors:  M A Polis; I A Sidorov; C Yoder; S Jankelevich; J Metcalf; B U Mueller; M A Dimitrov; P Pizzo; R Yarchoan; D S Dimitrov
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

3.  Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.

Authors:  Gerald Friedland; Saye Khoo; Christopher Jack; Umesh Lalloo
Journal:  J Antimicrob Chemother       Date:  2006-10-10       Impact factor: 5.790

4.  Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control.

Authors:  Stephen D Lawn; Landon Myer; Linda-Gail Bekker; Robin Wood
Journal:  AIDS       Date:  2006-08-01       Impact factor: 4.177

5.  Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points.

Authors:  H Wu; D R Kuritzkes; D R McClernon; H Kessler; E Connick; A Landay; G Spear; M Heath-Chiozzi; F Rousseau; L Fox; J Spritzler; J M Leonard; M M Lederman
Journal:  J Infect Dis       Date:  1999-04       Impact factor: 5.226

6.  The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.

Authors:  R M Hoetelmans; M H Reijers; G J Weverling; R W ten Kate; F W Wit; J W Mulder; H M Weigel; P H Frissen; M Roos; S Jurriaans; H Schuitemaker; F de Wolf; J H Beijnen; J M Lange
Journal:  AIDS       Date:  1998-07-30       Impact factor: 4.177

7.  Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis.

Authors:  Yuan Ren; James J C Nuttall; Brian S Eley; Tammy M Meyers; Peter J Smith; Gary Maartens; Helen M McIlleron
Journal:  J Acquir Immune Defic Syndr       Date:  2009-04-15       Impact factor: 3.731

8.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

9.  Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients.

Authors:  Lynn Morris; Desmond J Martin; Helba Bredell; Stephina N Nyoka; Leonard Sacks; Stella Pendle; Liesl Page-Shipp; Christopher L Karp; Timothy R Sterling; Thomas C Quinn; Richard E Chaisson
Journal:  J Infect Dis       Date:  2003-06-04       Impact factor: 5.226

10.  Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa.

Authors:  Stephen D Lawn; Landon Myer; David Edwards; Linda-Gail Bekker; Robin Wood
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177
View more
  4 in total

Review 1.  The effect of tuberculosis treatment on virologic and CD4+ cell count response to combination antiretroviral therapy: a systematic review.

Authors:  Heidi M Soeters; Sonia Napravnik; Monita R Patel; Joseph J Eron; Annelies Van Rie
Journal:  AIDS       Date:  2014-01-14       Impact factor: 4.177

Review 2.  Representation of women and pregnant women in HIV research: a limited systematic review.

Authors:  Daniel Westreich; Molly Rosenberg; Sheree Schwartz; Geeta Swamy
Journal:  PLoS One       Date:  2013-08-23       Impact factor: 3.240

Review 3.  The effect of tuberculosis treatment at combination antiretroviral therapy initiation on subsequent mortality: a systematic review and meta-analysis.

Authors:  Heidi M Soeters; Charles Poole; Monita R Patel; Annelies Van Rie
Journal:  PLoS One       Date:  2013-10-15       Impact factor: 3.240

4.  Virologic and immunologic outcome of HAART in Human Immunodeficiency Virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, Ethiopia.

Authors:  Desta Kassa; Gebremedhin Gebremichael; Yodit Alemayehu; Dawit Wolday; Tsehaynesh Messele; Debbie van Baarle
Journal:  AIDS Res Ther       Date:  2013-07-10       Impact factor: 2.250
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.